ReviewEuropean journal of endocrinology2018
MANAGEMENT OF ENDOCRINE DISEASE: Novel anabolic treatments for osteoporosis.
Review in European journal of endocrinology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 2 syntheses or guidelines pooled it, 89 citations in OpenAlex.
- Impact of anti-osteoporosis medication on refracture prevention following osteoporotic vertebral fracture: a systematic review and meta-analysis.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2025Pooled it
- Osteoporosis in COPD patients: Risk factors and pulmonary rehabilitation.The clinical respiratory journal · 2022Pooled it
- Levels of serum sclerostin, FGF-23, and intact parathyroid hormone in postmenopausal women treated with calcitriol.Clinical interventions in aging · 2018Trial
- Role of denosumab in lipid metabolism disorders: clinical significance and potential mechanisms.Archives of osteoporosis · 2025Review
- Surgical Management of Adult Spinal Deformity Patients with Osteoporosis.Journal of clinical medicine · 2024Review
- Personalized Approaches to Spine Surgery.International journal of spine surgery · 2024Article
- Successful treatment of adjunctive teriparatide therapy for medication-related osteonecrosis of the jaw: a report of two cases.Journal of the Korean Association of Oral and Maxillofacial Surgeons · 2024Article
- RANK-RANKL-OPG Axis in MASLD: Current Evidence Linking Bone and Liver Diseases and Future Perspectives.International journal of molecular sciences · 2024Review
- Mechanistic Insights and Therapeutic Strategies in Osteoporosis: A Comprehensive Review.Biomedicines · 2024Review
- Article
- Review
- Traditional Chinese medicine in osteoporosis: from pathogenesis to potential activity.Frontiers in pharmacology · 2024Review
- Transcriptome Sequencing Identifies Abnormal lncRNAs and mRNAs and Reveals Potentially Hub Immune-Related mRNA in Osteoporosis with Vertebral Fracture.Clinical interventions in aging · 2024Article
- Article
- Medical optimization of osteoporosis for adult spinal deformity surgery: a state-of-the-art evidence-based review of current pharmacotherapy.Spine deformity · 2023Review
- Bioactivity, Molecular Mechanism, and Targeted Delivery of Flavonoids for Bone Loss.Nutrients · 2023Review
- Relative comparison of chronic kidney disease-mineral and bone disorder rat models.Frontiers in physiology · 2023Article
- Controversial causal association between IGF family members and osteoporosis: a Mendelian randomization study between UK and FinnGen biobanks.Frontiers in endocrinology · 2023Article
- Skeletal disorders associated with the growth hormone-insulin-like growth factor 1 axis.Nature reviews. Endocrinology · 2022Review
- Yukmijihwang-Tang Suppresses Receptor Activator of Nuclear Factor Kappa-B Ligand (RANKL)-Induced Osteoclast Differentiation and Prevents Ovariectomy (OVX)-Mediated Bone Loss.Molecules (Basel, Switzerland) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
Skeletal anabolic agents enhance bone formation, which is determined by the number and function of osteoblasts. Signals that influence the differentiation and function of cells of the osteoblast lineage play a role in the mechanism of action of anabolic agents in the skeleton. Wnts induce the differentiation of mesenchymal stem cells toward osteoblasts, and insulin-like growth factor I (IGF-I) enhances the function of mature osteoblasts. The activity of Wnt and IGF-I is controlled by proteins that bind to the growth factor or to its receptors. Sclerostin is a Wnt antagonist that binds to Wnt co-receptors and prevents Wnt signal activation. Teriparatide, a 1-34 amino terminal fragment of parathyroid hormone (PTH), and abaloparatide, a modified 1-34 amino terminal fragment of PTH-related peptide (PTHrp), induce IGF-I, increase bone mineral density (BMD), reduce the incidence of vertebral and non-vertebral fractures and are approved for the treatment of postmenopausal osteoporosis. Romosozumab, a humanized anti-sclerostin antibody, increases bone formation, decreases bone resorption, increases BMD and reduces the incidence of vertebral fractures. An increased incidence of cardiovascular events has been associated with romosozumab, which is yet to be approved for the treatment of osteoporosis. In conclusion, cell and molecular studies have formed the foundation for the development of new anabolic therapies for osteoporosis with proven efficacy on the incidence of new fractures.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.